- 1 Major Article submitted *to Journal of Infectious Diseases*:
- 2 3

Regional differences in vaccine uptake and serological responses to vaccine and circulating strains of H1N1 viruses among patients with confirmed influenza

- 4 5
- 6 Ashley L. Fink¹, Hsuan Liu¹, Kathryn Shaw-Saliba^{1,2}, Thomas Mehoke³, Jared Evans³,
- 7 Zhen-Ying Liu⁴, Mitra Lewis², Lauren Sauer², Peter Thielen³, Kuan-Fu Chen⁴, Richard
- 8 Rothman², Sabra L. Klein^{1,5,6,*}, Andrew Pekosz^{1, 2, 7,*}
- 9
- ¹W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns
- 11 Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205 USA;
- ¹² ²Department of Emergency Medicine, Johns Hopkins University School of Medicine,
- 13 Baltimore, Maryland 21205 USA;
- ¹⁴ ³Research and Exploratory Development Department, Johns Hopkins Applied Physics
- 15 Laboratory, Laurel, Maryland 20723 USA;
- ⁴Department of Emergency Medicine, Clinical Informatics and Medical Statistics
- 17 Research Center, Keelung Chang Gung Memorial Hospital, Chang Gung University,
- 18 Keelung and Taoyuan City, 33302 Taiwan;
- ¹⁹ ⁵Department of Biochemistry and Molecular Biology, The Johns Hopkins Bloomberg
- 20 School of Public Health, Baltimore, Maryland 21205 USA;
- ⁶Department of International Health, The Johns Hopkins Bloomberg School of Public
- 22 Health, Baltimore, Maryland 21205 USA;
- ²³ ⁷Department of Environmental Health and Engineering, The Johns Hopkins Bloomberg
- 24 School of Public Health, Baltimore, Maryland 21205 USA.
- 25
- 26 **Running title:** Antibodies to H1N1 influenza viruses (40 characters max)
- 27 Key Words: H1N1 influenza, human surveillance, neutralizing antibody, seasonal
- 28 influenza vaccine
- 29 Manuscript statistics:
- 30 Abstract:
- 31 **Text: 3500 max (currently 3500)**
- 32 **Number of figures:** 4 (7 tables and figures max; 4 panels per figure)
- 33 **Number of tables:** 3 (can have up to 25 MB of online suppl info)
- 34 **References:**
- 35 **Financial support:** This work was supported by the NIH/NIAID Center of Excellence in
- 36 Influenza Research and Surveillance contracts HHS N272201400007C and HHS
- 37 N272201400006C.
- 38 **Disclosures:** The authors report no conflicts of interest
- 39
- 40 *Correspondence:
- 41 Sabra L. Klein, Ph.D., <u>sklein2@jhu.edu</u>, 410-955-8898
- 42 Andrew Pekosz, Ph.D., apekosz1@jhu.edu , 410-502-9306
- 43

Fink et al. 2

44	Background. Seasonal epidemics of influenza are often characterized through national
45	or international surveillance efforts to determine vaccine efficacy and vaccine strain
46	selection, but they do not provide detailed information about local variations in factors
47	that can influence influenza cases and disease severity.
48	
49	Methods. Surveillance for influenza like illness was performed in Emergency Medicine
50	Departments in Taipei, Taiwan and Baltimore, Maryland during the winter of 2015-16.
51	Detailed demographic and clinical data were obtained. Nasal swabs or washes were
52	collected for influenza virus diagnosis, sequencing and isolation. Serum was collected
53	to determine neutralizing antibody levels.
54	
55	Results. H1N1 viruses dominated both sites, but more influenza cases occurred in
56	Taipei compared to Baltimore. H1 HA clade diversity was greater in Taipei. Vaccination
57	rates were lower in Taipei than Baltimore, but vaccination was associated with an
58	increase in serum neutralizing antibodies to recent H1N1 strains in Taipei, but not
59	Baltimore. There was a higher level of preexisting immunity to circulating H1N1 strains
60	in Baltimore.
61	
62	Conclusions. Regional differences in preexisting immunity and H1N1 strain circulation
63	may have contributed to the vastly different 2015-16 influenza seasons in Taipei and
64	Baltimore and suggest immune responses to vaccination can be affected by the degree

65 of preexisting immunity in the population.

Fink et al. 3

Influenza causes disease in the human population and the specific strain of virus that is circulating, the levels of preexisting immunity to circulating viruses, vaccine uptake, vaccine strain match to circulating virus strains, and the presence of mutations that modulate virus fitness all contribute to the magnitude of seasonal cases and disease severity [1, 2]. Other factors impact the susceptibility to influenza in a strain independent manner, including age, immune status, pregnancy, gender, and the presence of comorbidities [2-4].

73

74 The 2015-16 influenza season in the Northern hemisphere was dominated by H1N1 75 Influenza A virus, with significant differences in the number of cases and disease 76 severity across different countries [5]. In contrast, East and Southeast Asia experienced 77 a particularly strong influenza season [5]. Serological assays using ferret antiserum 78 indicated circulating H1N1 viruses were antigenically similar to the 2015-16 vaccine 79 strain [6-9]. Surveillance for influenza-like illness (ILI) in 2015-16 was performed in the 80 Emergency Departments (ED) of Chang Gung Memorial Hospital (CGMH), Taipei, 81 Taiwan and the Johns Hopkins Medical Institution (JHMI), Baltimore, Maryland. The 82 influenza season in Taipei was more severe than in Baltimore and factors including 83 differences in circulating virus strains, vaccination rates, serum neutralizing antibody 84 levels after vaccination, antibody cross reactivity between vaccine and circulating 85 strains, and levels of preexisting immunity contributed to the different influenza seasons 86 at the two surveillance sites.

87

88 Materials and Methods

Fink et al. 4

89 Human sample collection and ethics

90	The human subjects protocol was reviewed and approved by the JHMI Institutional
91	Review Board (IRB) and the CGMH IRB (IRB00052743). This protocol allowed for the
92	enrollment of influenza positive, negative, and asymptomatic patients from the JHMI
93	and CGMH ED with informed consent. For each patient, nasal pharyngeal (NP) swab or
94	nasal wash (NW) and 10 ml of blood were collected at enrollment (i.e., time of
95	presentation and positive influenza test, \leq 7 days after the onset of symptoms). NP
96	swabs were tested for influenza A virus using the CepheidGeneExpert $\ensuremath{\mathbb{C}}$ test. Blood was
97	collected in Vacutainer tubes (BD), serum was separated and stored at -70°C. The
98	patient's basic demographics (i.e., age, ethnicity, race, gender, co-morbidities, and
99	medications) were collected using data collection forms. Disease severity data (i.e., use
100	of oxygen, hospital admission, disease outcomes) were collected during a follow up
101	conversation and by chart review. For vaccination status, patients were asked if they
102	received an influenza vaccine for the current season (2015-2016).

103

104 Virus sequencing and phylogenetic analysis

Viral RNA isolation and sequencing was performed as previously described [10, 11] and the phylogenetic analysis was performed as previously described [12] by comparing the full-length nucleotide sequence of the hemagglutinin (HA) open reading frame from representative strains of all clades of H1N1 2009 pandemic viruses retrieved from the Global initiative on sharing all influenza data (GISAID). Trees were viewed and colored using FigTree and HA clades were identified by adding known clade references to these trees and identifying branches for the 6B, 6B.1, and 6B.2 clades. Clade 6B.1 was

Fink et al. 5

112	defined by HA1 amino acid substitutions S84N, S162N and I216T; and clade 6B.2 was
113	defined by HA1 amino acid substitutions V152T and V173I and HA2 amino acid
114	substitutions E164G and D174E. Sequences generated in the study were submitted to
115	GenBank NCBI Influenza Virus Database (Supplementary Table 1).
116	
117	Cell cultures
118	Madin-Darby canine kidney (MDCK) cells were used to grow all viruses and were
119	cultured in Dulbecco's modified Eagle medium (DMEM; Sigma) with 10% fetal bovine
120	serum (Gibco), 100 μ g/ml of penicillin and 100 μ g/ml of streptomycin (Quality
121	Biological), and Glutamax (Gibco) at 37° C and 5% CO ₂ . Human nasal epithelial cell
122	(hNEC) cultures were isolated from non-diseased tissue after endoscopic sinus surgery
123	for non-infection related conditions and grown at air-liquid interface (ALI). The hNEC
124	isolation, differentiation and culture conditions have been described in detail previously
125	[13].
126	
127	Vaccine viruses
128	A recombinant influenza virus encoding the HA protein derived from the sequence of
129	A/Michigan/45/2015-like egg-adapted virus (A/Mich/45/15; GISAID Accession no.:
130	EPI685579) was used as the A/Mich/45/15 vaccine virus for serology assays. The HA
131	protein has an egg-adapted mutation at position 223 (glutamine (Q) to arginine (R);
132	Q223R) on the HA protein. A/Mich/45/15 virus was generated using a 12-plasmid
133	influenza reverse genetic system [14, 15] with plasmids encoding the HA and the

Fink et al. 6

134	neuraminidase (NA) of the A/Mich/45/15-like virus and the remaining 6 viral gene
135	segments derived from A/California/7/2009 (A/Cal/7/09) as described previously [16].
136	
137	Viral isolates from clinical samples used for serology and growth analysis
138	Fluids from NP swabs or NW from influenza A virus positive individuals were used to
139	isolate viruses by inoculating primary, differentiated hNEC cultures as previously
140	described [12]. A representative viral isolate from each clade was used for serology
141	assays and growth analysis on hNECs. The representative viral isolates used, include:
142	A/Baltimore/0026/2016 (JHMI 6B.1), A/Linkou/0032/2015 (CGMH 6B.1),
143	A/Linkou/0029/2015 (CGMH 6B.2), and A/Linkou/0030/2015 (CGMH 6B).
144	
145	Virus growth curves and TCID ₅₀ assay
146	Low-multiplicity of infection (MOI) growth curves were performed in quadruplicate by
147	infecting hNECs in 24-well Transwell© inserts at an approximate MOI of 0.1 50% tissue
148	culture infectious units (TCID $_{50}$) per cell as described previously [15, 16].
149	
150	Ferret antisera
151	Ferrets (male, Triple F Farms, Sayre, PA) were lightly anesthetized with isoflurane and
152	intranasally inoculated with 10^6 TCID ₅₀ in 1 ml PBS of A/Baltimore/0026/2016 (6B.1)
153	(two ferrets) or A/Linkou/0029/2015 (6B.2) (two ferrets). After 21 days, animals were
154	sacrificed to obtain sera. Animal experiments were approved by the St. Jude Children's
155	Research Hospital Animal Care and Use Committee.
156	

Fink et al. 7

157 Serum neutralization assay

158 Human or ferret serum was used in microneutralization assays using MDCK cells as

159 previously described [10]. The neutralizing antibody titer was calculated as the highest

- serum dilution that eliminated virus cytopathic effects in 50% of the wells.
- 161

162 Statistical analysis

163 Serology data were analyzed with a 2-way ANOVA followed by pairwise multiple

164 comparisons or by 1-way ANOVA or students t-test. Fold change in antibody titers

165 between different virus strains and across different sites were analyzed by Chi-square

analysis. Virus replication kinetics were analyzed using a repeated measures 2-way

167 ANOVA. Clinical data in tables 1-3 were analyzed by Chi-square analysis.

168

169 For multivariate analyses, the antibody titers were log transformed. All variables with p < p170 0.2 and beta coefficient > 0.1 in the bivariate linear regression were evaluated with 171 multivariate linear regression with Allen-Cady backward selection procedure, with 172 priority determined by clinical relevance and existing literature support. We adopted the 173 Akaike's Information Criteria and the Chi-square goodness of fit test to evaluate the 174 model fitness. Interaction check was performed to evaluate the potential effect 175 modification between vaccination, antibody titers, and significant risk factors. Because of the relative small sample size, we further performed propensity score weighting 176 177 modeling, in order to simultaneously adjust multiple confounders. Confounders 178 considered to influence the causal relationship between vaccination and antibody titers 179 were modeled to generate the propensity of vaccination, with the propensity score used

Fink et al. 8

180	as the weight to balance the potential confounding and evaluate the average treatment
181	effect. Mean differences were considered statistically significant if p <0.05.

- 182
- 183 **Results**

184 Influenza surveillance was performed in the ED at JHMI and at CGMH from November 185 1, 2015 (week 44 of 2015) to April 30, 2016 (week 17 of 2016). The basic demographic 186 and disease characteristics of patients reporting with ILI that were either confirmed to be 187 infected (IAV+) or not (IAV-) in Baltimore (n=252) and in Taipei (n=245) are summarized 188 in **Table 1**. In Baltimore, there was a racial difference, in which more Caucasian/white 189 patients with ILI were IAV- (40.1%) than IAV+ (23.5%). For IAV vaccination in Baltimore, 190 50.3% of IAV- patients received the 2015-16 seasonal vaccine compared to 29.8% in 191 the IAV+ group. The Baltimore IAV- population had significantly more patients with 192 multiple co-morbidities (50.3%) than the IAV+ population (35.3%). There was also a 193 greater number of IAV- patients with ILI admitted to JHMI hospitals (44.3%) than IAV+ 194 patients (29.4%). In contrast, fewer differences were observed between the IAV+ and 195 IAV- individuals with ILI from the Taipei population. Greater numbers of females as 196 compared to males were present in the IAV+ group (65.5%) than the IAV- group 197 (52.6%) in Taipei.

198

Enrollment weeks for IAV+ individuals were plotted (Figure 1A and 1B). Influenza A
virus activity was lower and peaked later (mid-March; Figure 1A) in the Baltimore
population and was higher and peaked earlier (January-February; Figure 1B) in the

Fink et al. 9

Taipei population which was representative of the overall IAV activity in each country [6,7].

204

205	Among the 233 IAV+ cases across the surveillance sites, 111 NW or NP swabs were
206	processed for sequencing. H1N1 was the predominant IAV subtype circulating globally
207	[6, 17, 18] and in both Baltimore and Taipei (Figure 1A and 1B). One-hundred and
208	three of the isolates (92.8%) were identified as H1N1 viruses and only 8 (7.2%) were
209	H3N2 viruses. Seventy-nine of the 103 H1N1 clinical virus isolates yielded sufficient
210	coverage of the HA segment and all belonged to clade 6 subgroup B (clade 6B), 6B.1 or
211	6b.2 [19], with the latter two clades newly emerged in this season [20]. Phylogenetic
212	analysis of the HA gene sequences from patients in Baltimore (red) or Taipei (blue)
213	classified most isolates as clade 6B.1. Clade 6B.2 viruses made up a significant number
214	of the isolates in Taipei, but were absent in Baltimore (Figure 2A and 2B).
215	
216	A comparison of the patient populations of Baltimore and Taipei that were infected with
217	H1N1 viruses revealed that these populations were similar in terms of demographics
218	and disease severity (Table 2), with expected differences in race observed between
219	sites. More patients with no known co-morbidities for severe influenza were infected in
220	the Taipei population compared to Baltimore. Vaccine coverage was higher in the
221	Baltimore population (31.6%) than the Taipei population (4.7%). These data show
222	stronger influenza activity and H1N1 infection in Taipei compared to Baltimore.

Fink et al. 10

224	Outside of race, there were no differences in the clinical or demographic characteristics
225	of patients infected with clade 6B.1 viruses in Baltimore when compared to those
226	infected with 6B.1 viruses in Taipei (Supplementary Table 2). Among patients infected
227	with clade 6B.1 viruses at the two sites, there were no significant demographic
228	differences. Likewise, there were no differences in Taipei patients infected with 6B.1
229	compared to 6B.2 viruses (Supplementary Table 2), indicating that the disease
230	incidence and severity differences between the Baltimore and Taipei sites were not
231	driven by any specific demographic or clinical factor.
232	

233 The amino acid mutations in the HA protein of circulating virus strains were mapped on 234 the H1 HA protein crystal structure (Figure 2C). Clade 6B.1 viruses were characterized 235 by mutations S84N, S162N, and I216T (purple), with an amino acid residue 162 on the 236 Sa antigenic site (blue). Amino acid 216, along the 220 loop of the receptor-binding 237 domain was adjacent to the Sb antigenic site (pink). The I216T mutation may be a 238 compensatory mutation as a result of the S162N mutation [21]. Clade 6B.2 viruses 239 contained two HA1 mutations: V152T, adjacent to the Sa and Sb antigenic sites and 240 V173I, near the Ca1 antigenic site (yellow). In addition to the mutations in HA1, 6B.2 241 viruses contained two mutations in HA2: E164G and D174E which were both on the 242 surface of the HA stalk domain (Figure 2C). When compared to the vaccine strain 243 A/Cal/7/09, both clade 6B.1 and 6B.2 viruses had 11 additional amino acid mutations 244 (P83S, D97N, K163Q, S185T, S203T, A256T, K283E, I321V and HA2: E47K, S124N, 245 and E172K), many of which were located on or near antigenic sites.

Fink et al. 11

247	The replication efficiency of 6B.1 and 6B.2 clinical virus isolates was assessed using
248	hNEC cultures. No significant differences in virus replication kinetics were detected
249	(Figure 2D) with viruses isolated from the two surveillance sites.
250	
251	Influenza-specific antibodies are considered the primary correlate of protection against
252	influenza infection in humans [22]. Neutralizing antibody responses to the clade 6B.1
253	virus were greater in patients from Baltimore than Taipei in serum collected at the time
254	of enrollment (Figure 3A). The higher titer of anti-clade 6B.1 antibodies, but not
255	antibodies to the vaccine strain, in the Baltimore population indicated higher titers of
256	antibodies to circulating viruses that do not cross react with the vaccine strain and
257	suggested that human antibodies can differentiate between the H1N1 circulating and
258	vaccine strains.

259

260 We compared individuals that received the 2015-16 seasonal influenza vaccine with 261 those that did not across the two surveillance sites. Although receipt of the seasonal 262 vaccine did not affect neutralizing antibody responses to the vaccine or circulating 263 viruses in patients from Baltimore (Figure 3B), neutralizing antibody responses from 264 Taipei patients were significantly greater in vaccinated compared to unvaccinated 265 patients (Figure 3C). We conclude that geographic location and presumably the history 266 of exposure to circulating and vaccine strains of influenza impact the antibody response 267 induced by vaccination.

Fink et al. 12

269	The H1N1 component of the seasonal influenza vaccine was updated for the 2017-18
270	influenza season from A/Cal/7/09 to clade 6B.1 A/Mich/45/15 [23], so we hypothesized
271	that the baseline neutralizing antibody responses to this virus would be similar to
272	responses to the 2015-16 circulating clade 6B.1 viruses. Both vaccinated and
273	unvaccinated patients from Baltimore had cross-reactive neutralizing antibody
274	responses to the A/Mich/45/15 vaccine virus, whereas in Taipei only vaccinated
275	individuals had cross-reactive neutralizing antibody responses as compared to
276	unvaccinated individuals (Figure 4A), indicating that vaccination could have regional
277	differences in the induction of cross-reactive antibody responses.
278	
279	We analyzed the baseline neutralizing antibody titers to the A/Cal/7/09 and the
280	A/Mich/45/15 vaccine strain. The serum cross-reactivity to the A/Mich/45/15 vaccine
281	virus as compared to the A/Cal/7/09 vaccine virus was greater in Baltimore compared
282	Taipei using a ≥ 4 fold increase in titer as a cutoff (Figure 4B) which was driven by
283	differences among unvaccinated patients at the two surveillance sites. Using a more
284	stringent cutoff of \geq 8 fold increase in titer, there was still greater recognition of the
285	A/Mich/45/15 vaccine virus among patients from Baltimore as compared to those from
286	Taipei, with both unvaccinated and vaccinated populations driving the cross-site
287	differences (Figure 4B), indicating there are regional differences in the recognition of
288	vaccine strains and the circulating 6B.1 viruses (Figure 3A and 4A).
289	

The antigenic characterization of IAV isolates is traditionally measured in HAI assays
using strain specific, post-infection ferret antisera [24] and HAI assays showed ferret

Fink et al. 13

292	sera raised to circulating reference 6B.1 and 6B.2 viruses cross-reacted well with the
293	A/Cal/7/09 vaccine virus [19]. Using sera from ferrets infected with the circulating H1N1
294	virus strains from Baltimore and Taipei, there were greater neutralizing antibody
295	responses to the clade 6B virus as compared with the A/Cal/7/09 vaccine virus (Figure
296	4C). All ferrets had a \geq 4 fold increase in titer specific to each of the circulating virus
297	strains as compared to the A/Cal/7/09 vaccine strain (Figure 4D). Our data showed low
298	cross-reactivity between the ferret sera raised to circulating H1N1 strains and the
299	A/Cal/7/09 vaccine strain, indicating potential antigenic differences between the
300	circulating and vaccine strains, and supporting the recommendation to update the H1N1
301	component of the seasonal influenza vaccine.

302

303 Using an Allen-Cady modified stepwise multivariable regression model to control for 304 confounding variables revealed increased age was consistently associated with lower 305 titers (**Table 3**). In contrast, a significant association between age and neutralizing 306 antibody titers in our univariate analysis was not observed (**Supplementary Figure 1**). 307 Other factors that were associated with lower titers in different clades included male 308 gender (A/Cal/7/09, 6B.1), steroid usage (6B), higher BMI (6B.2), being Asian (6B.1), 309 and some socioeconomic factors. Although we did not observe gender differences in 310 baseline neutralizing antibody titers in our univariate analysis (Supplementary Figure 311 **2**), previous studies have established that males tend to have significantly lower 312 neutralizing antibody titers to influenza as compared with females [25]. Receipt of the 313 influenza vaccine was associated with higher baseline neutralizing antibody titers to the 314 A/Cal/7/09 vaccine strain virus and the clade 6B and 6B.2 circulating viruses. In a

Fink et al. 14

315 propensity score weighting model, receipt of the influenza vaccine resulted in higher 316 neutralizing antibody titers to all viruses except the clade 6B.1 virus. In the multivariable 317 regression, when the variable "Asian" was removed, vaccination was still significantly 318 associated with higher baseline neutralizing antibody titers, indicating that there could 319 be a confounding effect between being Asian and receipt of the influenza vaccine. In the 320 effect modification multivariable regression analysis, we found that vaccinated patients 321 from Taipei had consistently higher antibody titers across different clades, except 6B.2 322 (Table 3). The observation that receipt of the influenza vaccine was associated with 323 higher baseline neutralizing antibody titers to all viruses except the clade 6B.1 virus 324 further confirms the recommendation to update the H1N1 vaccine virus to A/Mich/45/15, 325 which is a clade 6B.1 virus.

326

327 Discussion

This study illustrates differences in influenza activity, pre-existing influenza immunity, and virus strain circulation in the 2015-16 influenza season across surveillance sites located in Baltimore, Maryland and Taipei, Taiwan. We conclude that regional factors as well as host demographic variables, including age, gender, and BMI, may play important roles in modulating receipt of seasonal influenza vaccines, vaccine-induced immunity, and severity of influenza disease.

334

The 2015-16 influenza season was characterized by increased H1N1 influenza cases in Taipei compared to Baltimore, with differences in the HA clades that circulated at each site, consistent with previous reports [26-28]. Clade 6B.2 viruses circulated in primarily

Fink et al. 15

338	in Asia but never became a common clade globally. While specific amino acid changes
339	near antigenic sites are present in clade 6B.2 viruses, they appear to be antigenically
340	indistinguishable from clade 6B.1 viruses using human and ferret serum. Both H1N1
341	clades had similar replication kinetics in hNEC cultures, indicating there were no
342	inherent differences in virus fitness between the two clades. Since the 2016-17 season,
343	only H1N1 6B.1 viruses have been detected and have evolved to different clade 6B.1
344	subclades which are continuing circulation worldwide [23, 29-32].
345	
346	The demographic characteristics of the Baltimore and Taipei sites were similar, except
347	for race. It is difficult to ascertain the contribution of race to influenza susceptibility given
348	these differences. There was a significantly larger number of influenza cases in

individuals with no known influenza co-morbidities in Taipei compared to Baltimore,

indicating a greater degree of susceptibility in the population in Taipei, which is

351 supported by the overall lower vaccine rate and levels of neutralizing antibodies to

352 circulating human H1N1 present in that population. The overall lower antibody titers to

353 6B.1 viruses in Taipei were surprising given that antigenically related viruses have been

354 circulating globally since 2009. Vaccination, however, did not affect neutralizing

antibody titers in patients from Baltimore, perhaps due to higher levels of preexisting

356 H1N1 immunity in that population. These data suggest that regional differences in

357 influenza vaccine uptake and immune responses to vaccination are present and can

impact the overall susceptibility of the population to influenza virus infection.

Fink et al. 16

360	Global 2015-16 influenza surveillance in most countries indicated the circulating H1N1
361	viruses were antigenically similar to the vaccine A/Cal/7/09 [6-9, 17, 33, 34]. In our
362	study, antigenic differences between the H1N1 vaccine strain and circulating viruses in
363	2015-16 were detected using human serum and serum from ferrets infected with
364	circulating H1N1 viruses in neutralization assays. Consistent with those observations,
365	higher neutralizing antibody responses to the A/Mich/45/15 vaccine strain compared to
366	the A/Cal/7/09 vaccine strain were detected. Studies also showed that humans elicited
367	differential antibodies recognizing cell-derived or egg-adapted vaccines which was
368	driven by the egg-adaption mutation Q226R (which is Q223R in H1 numbering) of
369	A/Cal/7/09, thus causing some individuals to better recognize the vaccine strain in HAI
370	assays [35-37]. However, we did not see significant differences in neutralization titers of
371	6B.1 circulating virus compared to the A/Mich/45/15 vaccine containing Q223R (Figure
372	3A 6B.1 and Figure 4A). Even though ferret antiserum were unable to distinguish
373	between A/Cal/7/09 and A/Mich/45/15, the WHO changed the H1N1 vaccine component
374	to A/Mich/45/15 in the 2017 Southern hemisphere vaccine and subsequently in the
375	2017-18 Northern hemisphere because circulating viruses were poorly recognized by
376	some post-vaccination adult human serum [38, 39]. Our use of human sera and virus
377	neutralization assays strongly indicate antigenic differences between the vaccine and
378	circulating strains.

379

We did not observe any relationship between neutralizing antibody titers and specific
age-ranges [40-43], but this is most likely due to small sample sizes in most age groups.
Although more females presented as IAV+, at least in Taipei, male gender, steroid use,

Fink et al. 17

and higher BMI correlated with lower neutralizing titers, as these are associated with an
 impaired humoral immune response [44, 45].

385

386 There are limitations of this study. Our acute influenza detection protocol does not 387 include pediatric patients so we are unable to assess preexisting immunity and case 388 numbers in age groups <18 years of age. Because only one surveillance site is used in 389 each country, we are unable to capture any regional differences within the United States 390 or Taiwan. Finally, the limited number of patients enrolled in our studies prevents us 391 from assessing the significance of a number of clinical and demographic factors on 392 influenza susceptibility and disease severity. 393 394 Although seasonal influenza epidemics are global, regional differences in human 395 populations can impact the number and severity of influenza cases most likely through 396 different exposure histories to circulating and vaccine strains. Vaccine efficacy and 397 preexisting immunity to vaccine and circulating strains should be characterized at the 398 local, national, and global levels to achieve accurate and complete assessments of the

399 factors that impact influenza in any year.

Fink et al. 18

401

402 Acknowledgements

- 403 We would like to thank the clinical coordinators at JHMI and CGMH who were
- 404 responsible for the data and sample collection. We also thank Stacey Schultz-Cherry,
- 405 Victoria Meliopoulos, and the St. Jude Center of Excellence in Influenza Research and
- 406 Surveillance (CEIRS) for providing the ferret antisera. We thank Deena Blumenkrantz
- 407 and Robert Stenzel for providing technical assistance in growing influenza viruses and
- 408 Dr. Andrew Lane for providing hNEC cultures.

409 **Funding**

- 410 This work was supported by the NIH/NIAID Center of Excellence in Influenza Research
- 411 and Surveillance contract HHS N2772201400007C (R.R., K.F.C., S.L.K and A.P.), T32
- 412 Al007417 (A.L.F.), the Richard Eliasberg Family Foundation and the Research Center
- 413 for Emerging Viral Infections from The Featured Areas Research Center Program within
- 414 the framework of the Higher Education Sprout Project by the Ministry of Education
- 415 (MOE) in Taiwan and the Ministry of Science and Technology (MOST), Taiwan MOST
- 416 109-2634-F-182-001 (Y.N.G.).

Fink et al. 19

418 **Figure legends**

419 Figure 1. Numbers of Influenza A virus isolates defined by clades with enrollment 420 dates in the two surveillance sites, Baltimore (JHMI) and Taipei (CGMH). Samples 421 collected from patients with influenza-like illness (ILI) between week 44 2015 (starting 422 Nov 2015) and week 16 2016 (ending April 2016) were tested for influenza A viruses 423 (IAVs) and the IAV+ samples were subtyped and clade-defined by deep sequencing. (A) 424 JHMI, (B) CGMH. Enrollments at week 6 of 2016 in Taipei were paused due to the 425 Chinese New Year holidays. 426 Figure 2. H1N1 HA phylogenetic analysis from clinical virus isolates. Clinical nasal 427 428 pharyngeal (NP) swabs or nasal washes (NW) of IAV+ patients from Baltimore (JHMI) 429 and Taipei (CGMH) were used to sequence the HA gene segment by deep sequencing. 430 (A) HA phylogenetic tree representing the 2015-16 H1N1 viruses from individuals at 431 Baltimore (red) and Taipei (blue) along with the 2015-16 vaccine strain 432 A/California/7/2009 (green) and the 2017-18 vaccine strain A/Michigan/45/2015 (green). 433 Representative isolates for serology assays and growth analysis are highlighted in 434 yellow. (B) Numbers of clinical virus isolates in clades 6B.1, 6B.2 and 6B were 435 identified. (C) HA protein structure of the clade 6B.1 and 6B.2 viruses are shown on a 436 H1 HA crystal structure of H1N1 virus (PDB:3LZG) using PyMOL. Antigenic sites Sa, 437 Sb, Ca1, Ca2, and Cb are indicated [46]. Amino acids are used to defined 6B.1 (purple) 438 and 6B.2 (pink) and other amino acid differences compared with A/California/7/2009 439 (dark green) are indicated. Enlarged 6B.2 head shows that aa173 (in pick spheres) is 440 not on the surface of HA, and is under site Ca1 (in sticks). (D) Viruses isolated from

Fink et al. 20

441	individuals at both Baltimore and Taipei were propagated on hNECs. Multistep growth
442	curves were performed on hNECs at 32°C with the representative viral isolates: clade
443	6B.1 virus from Baltimore and of clade 6B.1, 6B.2, and 6B viruses from Taipei.
444	Representative data from 2 independent experiments are shown. Dotted line indicates
445	limit of detection.
446	
447	Figure 3. Baseline human serum neutralizing antibody titers to vaccine and
448	circulating strains of H1N1. Human serum was collected at the time of enrollment and
449	neutralizing antibody (nAb) titers to the vaccine strain A/Cal/7/09, and representative
450	circulating strains 6B.1, 6B.2, and 6B were determined by neutralization assay. (A)
451	Baseline neutralizing antibody titers from individuals at Taipei (CGMH) (n=46) and
452	Baltimore (JHMI) (n=45), (B) vaccinated individuals (n=22) and unvaccinated individuals
453	(n=23) from Baltimore, and (C) vaccinated individuals (n=7) and unvaccinated
454	individuals (n=39) from Taipei.
455	
456	Figure 4. Human and ferret serum reactivity to H1N1 vaccines strains. Human
457	serum was collected at the time of enrollment and neutralizing antibody (nAb) titers to
458	the H1N1 vaccine strains A/Cal/7/09 and A/Mich/45/15 were determined by
459	neutralization assay. (A) nAb titers to A/Mich/45/15 from vaccinated (n=22) and
460	unvaccinated (n=23) individuals from Baltimore (JHMI) and vaccinated (n=7) and
461	unvaccinated (n=39) individuals from Taipei (CGMH). To compare the baseline nAb
462	titers between vaccine strains A/Cal/7/09 and A/Mich/45/15, individual baseline nAb
463	titers to A/Mich/45/15 and A/Cal/7/09 in vaccinated and unvaccinated individuals from

Fink et al. 21

464	Baltimore and Taipei were plotted (B). Male ferrets were infected with either
465	A/Baltimore/0026/2016 (n=2) or A/Linkou/0029/2015 (n=2) and 21 days later serum was
466	collected to determine the neutralizing antibody responses to A/Cal/7/09 and 6B.1,
467	6B.2, and 6B circulating viruses (C). The individual ferret serum neutralizing antibody
468	responses to the A/Cal/7/09 virus as compared to the circulating strains (6B.1, 6B.2, 6B)
469	was then plotted (D).
470	
471	Supplementary Figure 1. Univariate analysis of baseline neutralizing antibody
472	titers based on estimated birth year. Each individual's baseline neutralizing antibody
473	titers to the A/Cal/7/09, 6B, 6B.2, and 6B.1 viruses were plotted against their estimated
474	birth year. Individuals from both sites (A), individuals from Baltimore (JHMI) (B) and
475	individuals from Taipei (CGMH) (C) are represented. Correlation analysis was
476	performed and no significant correlations were observed.
477	
478	Supplementary Figure 2. Univariate analysis of gender differences in baseline
479	neutralizing antibody titers. Baseline neutralizing antibody titers to the A/Cal/7/09, 6B,
480	6B.2, and 6B.1 viruses were evaluated in individuals from Baltimore (JHMI) and Taipei
481	(CGMH) and data were stratified by gender. Data were first stratified by gender alone
482	(A) and then further stratified based on both gender and vaccine status (B).
483	

Fink et al. 22

484 **References**

- 485
- 486 1. Petrova VN, Russell CA. The evolution of seasonal influenza viruses. Nat Rev Microbiol
 487 2018; 16:60.
- 488 2. Paules C, Subbarao K. Influenza. Lancet **2017**; 390:697-708.
- 489 3. vom Steeg LG, Klein SL. SeXX Matters in Infectious Disease Pathogenesis. PLoS Pathog
- 490 **2016**; 12:e1005374.
- 491 4. Vermillion MS, Klein SL. Pregnancy and infection: using disease pathogenesis to inform
- 492 vaccine strategy. NPJ Vaccines **2018**; 3.
- 493 5. World_Health_Organization. Weekley epidemiological record Nos. 51/52. Vol. 91,
 494 2016:601-24.
- 495 6. Davlin SL, Blanton L, Kniss K, et al. Influenza Activity United States, 2015-16 Season and
- 496 Composition of the 2016-17 Influenza Vaccine. MMWR Morb Mortal Wkly Rep 2016;
 497 65:567-75.
- 498 7. Taiwan_CDC. Taiwan Influenza Express 2015-16 Flu Season 2016 Week 20. Available at:
 499 <u>https://www.cdc.gov.tw/En/File/Get/VCNkIvtTOiuP1vo1gJG89A</u>.
- 500 8. Chambers C, Skowronski DM, Sabaiduc S, et al. Interim estimates of 2015/16 vaccine
- effectiveness against influenza A(H1N1)pdm09, Canada, February 2016. Euro Surveill
 2016; 21:30168.
- 503 9. Komissarov A, Fadeev A, Sergeeva M, et al. Rapid spread of influenza A(H1N1)pdm09
- 504 viruses with a new set of specific mutations in the internal genes in the beginning of
- 505 2015/2016 epidemic season in Moscow and Saint Petersburg (Russian Federation).
- 506 Influenza Other Respir Viruses **2016**; 10:247-53.
- 507 10. Ursin RL, Liu H, Powell HR, et al. Differential Antibody Recognition of H3N2 Vaccine and
- Seasonal Influenza Virus Strains Based on Age, Vaccine Status, and Sex in the 2017-2018
 Season. J Infect Dis 2020; 222:1371-82.
- 510 11. Zhou B, Donnelly ME, Scholes DT, et al. Single-reaction genomic amplification
- 511 accelerates sequencing and vaccine production for classical and Swine origin human
- 512 influenza a viruses. Journal of virology **2009**; 83:10309-13.
- 513 12. Blumenkrantz DR, Mehoke T, Shaw-Saliba K, et al. Identification of H3N2 NA and PB1-
- 514 F2 genetic variants and their association with disease symptoms during the 2014-15
- 515 influenza season. bioRxiv **2020**:2020.02.20.956979.
- 516 13. Fischer WA, 2nd, King LS, Lane AP, Pekosz A. Restricted replication of the live
- 517attenuated influenza A virus vaccine during infection of primary differentiated human
- nasal epithelial cells. Vaccine **2015**; 33:4495-504.
- 519 14. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A. Rescue of
- 520 influenza A virus from recombinant DNA. Journal of virology **1999**; 73:9679-82.
- 521 15. McCown MF, Pekosz A. The influenza A virus M2 cytoplasmic tail is required for
- infectious virus production and efficient genome packaging. Journal of virology 2005;79:3595-605.
- 524 16. Klein EY, Blumenkrantz D, Serohijos A, et al. Stability of the Influenza Virus
- 525 Hemagglutinin Protein Correlates with Evolutionary Dynamics. mSphere **2018**; 3.
- 526 17. Broberg E, Melidou A, Prosenc K, et al. Predominance of influenza A(H1N1)pdm09 virus
- 527 genetic subclade 6B.1 and influenza B/Victoria lineage viruses at the start of the 2015/16
- 528 influenza season in Europe. Euro Surveill **2016**; 21.

Fink et al. 23

- 529 18. Santos KC, Silva DB, Sasaki NA, Benega MA, Garten R, Paiva TM. Molecular epidemiology
- 530 of influenza A(H1N1)PDM09 hemagglutinin gene circulating in Sao Paulo State , Brazil:
- 531 2016 anticipated influenza season. Rev Inst Med Trop Sao Paulo **2017**; 59:e9.
- 532 19. European_Centre_for_Disease_Prevention_and_Control. Influenza virus characterisation
 533 summary Europe, May 2016. Available at:
- 534 <u>https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/influenza-</u>
 535 <u>virus-characterisation-may-2016.pdf.</u>
- 536 20. Bedford T, Neher R. Seasonal influenza circulation patterns and projections for 2016-
- 537 2017. Available at:
- 538 <u>https://github.com/nextstrain/static/blob/master/content/reports/01-flu-vaccine-</u>
 539 <u>selection/03-2016-september.md</u>.
- 540 21. Altman MO, Angel M, Košík I, et al. Hemagglutinin Glycan Clock Guides Human Influenza
 541 A Virus Evolution. bioRxiv 2017.
- 542 22. Soema PC, Kompier R, Amorij JP, Kersten GF. Current and next generation influenza
- 543 vaccines: Formulation and production strategies. Eur I Pharm Biopharm **2015**: 94:251-63.
- 544 23. Blanton L, Wentworth DE, Alabi N, et al. Update: Influenza Activity United States and
- 545 Worldwide, May 21-September 23, 2017. MMWR Morb Mortal Wkly Rep **2017**; 66:1043-
- 546 51.
- 547 24. Stohr K, Bucher D, Colgate T, Wood J. Influenza virus surveillance, vaccine strain
- selection, and manufacture. Methods Mol Biol **2012**; 865:147-62.
- 549 25. Engler RJ, Nelson MR, Klote MM, et al. Half- vs full-dose trivalent inactivated influenza
- 550 vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med
- **2008**; 168:2405-14.
- 26. Clark AM, DeDiego ML, Anderson CS, et al. Antigenicity of the 2015-2016 seasonal H1N1
 human influenza virus HA and NA proteins. PloS one 2017; 12:e0188267.
- 554 27. Uda K, Shoji K, Koyama-Wakai C, et al. Clinical characteristics of influenza virus-induced
- lower respiratory infection during the 2015 to 2016 season. J Infect Chemother 2018;
 24:407-13.
- 557 28. Zhao XN, Zhang HJ, Li D, et al. Whole-genome sequencing reveals origin and evolution of
- influenza A(H1N1)pdm09 viruses in Lincang, China, from 2014 to 2018. PloS one 2020;
 15:e0234869.
- 560 29. Blanton L, Alabi N, Mustaquim D, et al. Update: Influenza Activity in the United States
- 561 During the 2016-17 Season and Composition of the 2017-18 Influenza Vaccine. MMWR
- 562 Morb Mortal Wkly Rep **2017**; 66:668-76.
- 563 30. European_Centre_for_Disease_Prevention_and_Control. Influenza virus
- characterisation, summary Europe, June 2017: Stockholm: ECDC, **2017**.
- 565 31. Neher RA, Bedford T. nextflu: real-time tracking of seasonal influenza virus evolution in
- 566 humans. Bioinformatics **2015**; 31:3546-8.
- 567 32. Bedford T, Neher R. Seasonal influenza circulation patterns and projections for 2017-
- 568 2018. Available at: <u>https://nextflu.org/reports/feb-2017/</u>.
- 569 33. Pebody R, Warburton F, Ellis J, et al. Effectiveness of seasonal influenza vaccine in
- 570 preventing laboratory-confirmed influenza in primary care in the United Kingdom:
- 571 2015/16 mid-season results. Euro Surveill **2016**; 21.
- 572 34. Korsun N, Angelova S, Gregory V, Daniels R, Georgieva I, McCauley J. Antigenic and
- 573 genetic characterization of influenza viruses circulating in Bulgaria during the 2015/2016
- 574 season. Infect Genet Evol **2017**; 49:241-50.

Fink et al. 24

- 575 35. Garretson TA, Petrie JG, Martin ET, Monto AS, Hensley SE. Identification of human
- 576 vaccinees that possess antibodies targeting the egg-adapted hemagglutinin receptor
- 577 binding site of an H1N1 influenza vaccine strain. Vaccine **2018**; 36:4095-101.
- 578 36. Raymond DD, Stewart SM, Lee J, et al. Influenza immunization elicits antibodies specific
- for an egg-adapted vaccine strain. Nat Med **2016**; 22:1465-9.
- 580 37. Liu F, Tzeng WP, Horner L, et al. Influence of Immune Priming and Egg Adaptation in
- the Vaccine on Antibody Responses to Circulating A(H1N1)pdm09 Viruses After Influenza
- 582 Vaccination in Adults. J Infect Dis **2018**; 218:1571-81.
- 583 38. World_Health_Organization. Recommended composition of influenza virus vaccines for
- use in the 2017 southern hemisphere influenza season. Available at:
- 585 <u>https://www.who.int/influenza/vaccines/virus/recommendations/2017_south/en/</u>.
- 39. World_Health_Organization. Recommended composition of influenza virus vaccines for
- 587 use in the 2017- 2018 northern hemisphere influenza season. Available at:
- 588 <u>https://www.who.int/influenza/vaccines/virus/recommendations/2017_18_north/en/</u>.
- 589 40. Linderman SL, Chambers BS, Zost SJ, et al. Potential antigenic explanation for atypical
- 590 H1N1 infections among middle-aged adults during the 2013-2014 influenza season.
- 591 Proceedings of the National Academy of Sciences of the United States of America **2014**;
- 592 111:15798-803.
- 593 41. Flannery B, Smith C, Garten RJ, et al. Influence of Birth Cohort on Effectiveness of 2015-
- 2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza
 A(H1N1) Virus in the United States. J Infect Dis 2018; 218:189-96.
- 596 42. Skowronski DM, Chambers C, Sabaiduc S, et al. Beyond Antigenic Match: Possible Agent-
- 597 Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During
- the 2015-2016 Season in Canada. J Infect Dis **2017**; 216:1487-500.
- 43. Skowronski DM, Chambers C, Sabaiduc S, et al. A Perfect Storm: Impact of Genomic
- Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 20142015 Season. Clin Infect Dis 2016; 63:21-32.
- 602 44. Sheridan PA, Paich HA, Handy J, et al. Obesity is associated with impaired immune
- response to influenza vaccination in humans. Int J Obes (Lond) **2012**; 36:1072-7.
- 45 Vicin SL Delvers A Sey based biology and the rational design of influenza vacai
- 45. Klein SL, Pekosz A. Sex-based biology and the rational design of influenza vaccination
 strategies. J Infect Dis **2014**; 209 Suppl 3:S114-9.
- 606 46. Krause JC, Tumpey TM, Huffman CJ, et al. Naturally occurring human monoclonal
- 607 antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. Journal of
- 608 virology **2010**; 84:3127-30.
- 609

Figure 1



Enrollment Date (weeks 2015-2016)

Figure 2



Vaccine strains

References

Collection sites: **Baltimore** Taipei

В

Clade	Baltimore (n=26)	Taipei (n=53)
6B.1	24 (92.3%)	30 (56.6%)
6B.2	0 (0%)	20 (37.7%)
6B	2 (7.7%)	3 (5.7%)

6B.2







H1N1 virus strains

Figure 4

Α









Supplementary Figure 2



H1N1 virus strains

Β

		Baltimore			Taipei			
		ILI+, IAV+	ILI+, IAV-	p-value	ILI+, IAV+	ILI+, IAV-	p-value	
Age								
	18-49	70.6% (60/85)	64.7% (108/167)	0.3973	62.2% (92/148)	68.0% (66/97)	0.501	
	50-64	23.5% (20/85)	26.9% (45/167)	0.6483	25.0% (37/148)	24.7% (24/97)	1	
	65+	5.9% (5/85)	8.4% (14/167)	0.6166	12.8% (19/148)	7.2% (7/97)	0.2048	
Race								
	White	23.5% (20/85)	40.1% (67/167)	0.0114	0% (0/148)	0% (0/97)	1	
	Black or African American	67.1% (57/85)	54.5% (91/167)	0.0594	0% (0/148)	0% (0/97)	1	
	Asian	0% (0/85)	1% (1/167)	1	100% (148/148)	100% (97/97)	1	
	Other	9.4% (8/85)	4.8% (8/167)	0.1765	0% (0/148)	0% (0/97)	1	
Gender								
	Female	52.9% (45/85)	57.5% (96/167)	0.5051	65.5% (97/148)	52.6% (51/97)	0.0461	
	Male	47.1% (40/85)	42.5% (71/167)		34.5% (51/148)	47.4% (46/97)		
Vaccina	tion							
	Vaccinated	29.8% (25/84)	50.3% (82/163)	0.0028	6.1% (9/148)	12.4% (12/97)	0.1037	
Co-mor	bidities							
	None	35.3% (30/85)	19.8% (33/167)	0.0089	54.7% (81/148)	47.4% (46/97)	0.2392	
	One	29.4% (25/85)	29.9% (50/167)	1	20% (29/148)	29% (28/97)		
	Multiple	35.3% (30/85)	50.3% (84/167)	0.0319	25.7% (38/148)	23.7% (23/97)		
Pregnar	псу	6.7% (3/45)	3.2% (3/95)	0.3861	5.2% (5/97)	5.9% (3/51)	1	
Disease	severity							
	Oxygen supplementation	17.6% (15/85)	28.7% (48/167)	0.0648	23.0% (34/148)	17.5% (17/97)	0.3374	
	Intubation	0% (0/84)	0% (0/167)	1	1% (1/148)	3% (3/97)	0.3033	
	Inpatient	29.4% (25/85)	44.3% (74/167)	0.0288	31% (46/148)	44% (43/97)	0.0584	
	Length of stay	3 (1-12)	2 (1-21)	0.8824	5 (1-55)	6 (1-59)	0.8476	
	ICU	8.0% (2/25)	0% (0/74)	0.0618	4.3% (2/46)	7.0% (3/43)	0.6729	
	Pneumonia	18% (15/85)	28% (46/167)	0.1528	41% (60/148)	40% (39/97)	1	
	Death	0% (0/85)	0% (0/167)	1	4% (6/148)	0% (0/97)	0.0839	

Table 1. Patient characteristics at the two geographic locations, Baltimore and Taipei.

		H1N1		
		Baltimore	Taipei	p value
Age				
18	-49	79.5% (31/39)	75.0% (48/64)	0.64
50	-64	17.9% (7/39)	20.3% (13/64)	1
65	+	2.6% (1/39)	4.7% (3/64)	1
Race				
W	hite	10.3% (4/39)	0% (0/64)	0.0186
Bla	ack or African American	74.4% (29/39)	0% (0/64)	<0.0001
As	ian	0% (0/39)	100% (64/64)	<0.0001
Ot	her	15.4% (6/39)	0% (0/64)	0.0023
Gender				
Fe	male	48.7% (19/39)	65.6% (42/64)	0.1022
Ma	ale	51.3% (20/39)	34.4% (22/64)	
Vaccination				
Va	ccinated	31.6% (12/38)	4.7% (3/64)	0.0004
Co-morbiditi	es			
No	one	38.5% (15/39)	60.9% (39/64)	0.0414
Or	ne	33.3% (13/39)	22% (14/64)	0.2496
М	ıltiple	28.2% (11/39)	17.2% (11/64)	0.2194
Pregnancy		10.5% (2/19)	0% (0/42)	<0.0001
Disease seve	erity			
Ox	kygen supplementation	12.8% (5/39)	9.4% (6/64)	1
Int	ubation	0% (0/39)	0% (0/64)	1
Inp	patient	23.1% (9/39)	19% (12/64)	0.4286
Le	ngth of stay	3 (1-12)	6 (3-9)	0.2256
IC	U	11.1% (1/9)	0% (0/12)	0.45
Pr	eumonia	18% (7/39)	34% (22/64)	0.1149
De	eath	0% (0/39)	2% (1/64)	1

Table 2. Clinical and demographic characteristics of H1N1 IAV-infected patients at Baltimore and Taipei

		Model 1:	A/Cal/7/09		
Variable	Coefficient	959	% CI	p-Value	Coefficient
Age	-0.03	-0.04	-0.01	0.00	-0.04
Vaccination	2.01	1.48	2.54	0.00	1.82
Education	-0.78	-1.31	-0.26	0.00	-1.06
Male	-0.50	-0.99	-0.02	0.04	
Asian					
Employment					-0.99
BMI					
Steroid usage					-2.03
Vaccination	2 1 /	1 1 2	2 1 7	0.00	1 62
by PSW	2.14	1.12	5.17	0.00	1.05
Vaccination x	2.08	0.88	3 78	0.00	3 50
Asian**	2.00	0.00	5.20	0.00	5.50

Table 3. Allen-Cady multivariate analysis

*Education: college or higher, BMI: Body mass index

** Effect modification between antibody titers, vaccination and Asian; adjusted for age an-

Mode	l 2: 6B		Model 3: 6B.1				
95%	6 CI	p-Value	Coefficient	95%	% CI	p-Value	
-0.07	-0.01	0.00	-0.03	-0.06	0.00	0.02	
0.95	2.70	0.00					
-1.97	-0.15	0.02	-1.03	-1.90	-0.17	0.02	
			-1.02	-1.83	-0.22	0.01	
			-2.56	-3.36	-1.76	0.00	
-1.92	-0.06	0.04					
-3.98	-0.07	0.04					
0.32	2.94	0.01	1.14	-0.19	2.47	0.00	
1.71	5.30	0.00	2.70	0.76	4.64	0.01	

d eduation in model 1; age, eduation, steroid usage and employment in model 2; male, educatio

Model 4: 6B.2							
Coefficient	Coefficient 95% Cl p-Value						
-0.04	-0.06	-0.02	0.00				
2.20	1.44	2.97	0.00				
-0.04	-0.09	0.00	0.05				
2.63	0.69	4.58	0.01				
0.52	-1.15	2.19	0.54				

n in model 3; and BMI, chills and HIV or AIDS in model

Stroin nome		ConBonk accession no
Strain name	HA clade	
A/Baltimore/0008/2016	6B.1	KY487698
A/Baltimore/0026/2016	6B.1	KY950126
A/Baltimore/0065/2016	6B.1	KY950052
A/Baltimore/0076/2016	6B.1	KY487689
A/Baltimore/0077/2016	6B.1	KY950108
A/Baltimore/0088/2016	6B	KY487140
A/Baltimore/0091/2016	6B.1	KY615553
A/Baltimore/0092/2016	6B.1	KY487543
A/Baltimore/0096/2016	6B.1	KY615388
A/Baltimore/0097/2016	6B.1	KY487190
A/Baltimore/0101/2016	6B.1	KY487503
A/Baltimore/0103/2016	6B.1	KY487506
A/Baltimore/0104/2016	6B.1	KY487646
A/Baltimore/0107/2016	6B.1	KY487472
A/Baltimore/0110/2016	6B.1	KY615408
A/Baltimore/0117/2016	6B.1	KY487377
A/Baltimore/0118/2016	6B.1	KY615604
A/Baltimore/0122/2016	6B.1	KY615559
A/Baltimore/0124/2016	6B.1	KY487575
A/Baltimore/0125/2016	6B.1	KY487453
A/Baltimore/0158/2016	6B.1	KY487430
A/Baltimore/0163/2016	6B.1	KY487592
A/EastBaltimore/0103/2016	6B	KY487656
A/EastBaltimore/0107/2016	6B.1	KY487123
A/EastBaltimore/0119/2016	6B.1	KY615447
A/EastBaltimore/0141/2016	6B.1	KY487527
A/Keelung/0011/2015	6B.1	KY487251
A/Keelung/0013/2015	6B.1	KY949643
A/Keelung/0027/2016	6B.2	KY487340
A/Keelung/0029/2016	6B.1	KY487499
A/Keelung/0031/2016	6B.2	KY615480
A/Keelung/0038/2016	6B.2	KY487655
A/Keelung/0039/2016	6B.1	KY949887
A/Keelung/0042/2016	6B.2	KY487695
A/Keelung/0046/2016	6B.1	KY487149
A/Keelung/0053/2016	6B.1	KY487727
A/Keelung/0055/2016	6B.1	KY950148

Supplementary Table 1: Influenza A virus strains and assoicated GenBank accession numbers

A/Keelung/0056/2016	6B.1	KY487617
A/Keelung/0065/2016	6B.2	KY487219
A/Keelung/0068/2016	6B.1	KY615443
A/Linkou/0004/2015	6B.1	KY950124
A/Linkou/0029/2015	6B.2	KY950184
A/Linkou/0030/2015	6B	KY949802
A/Linkou/0032/2015	6B.1	KY949823
A/Linkou/0034/2015	6B	KY949991
A/Linkou/0039/2015	6B.1	KY949680
A/Linkou/0046/2016	6B.1	KY949679
A/Linkou/0047/2016	6B.2	KY949975
A/Linkou/0049/2016	6B.1	KY950223
A/Linkou/0050/2016	6B.2	KY949736
A/Linkou/0057/2016	6B.1	KY615390
A/Linkou/0060/2016	6B.2	KY615424
A/Linkou/0065/2016	6B.1	KY487702
A/Linkou/0068/2016	6B.1	KY615570
A/Linkou/0077/2016	6B.2	KY487687
A/Linkou/0084/2016	6B.2	KY487767
A/Linkou/0093/2016	6B.1	KY487613
A/Linkou/0097/2016	6B.1	KY615425
A/Linkou/0098/2016	6B.1	KY615441
A/Linkou/0099/2016	6B.1	KY487353
A/Taipei/0008/2015	6B.2	KY487478
A/Taipei/0015/2015	6B.1	KY487273
A/Taipei/0018/2016	6B.1	KY487725
A/Taipei/0021/2015	6B.1	KY487147
A/Taipei/0025/2016	6B.2	KY487209
A/Taipei/0030/2016	6B.1	KY487336
A/Taipei/0032/2016	6B.2	KY487330
A/Taipei/0037/2016	6B.2	KY487649
A/Taipei/0040/2016	6B.1	KY487744
A/Taipei/0045/2016	6B	KY487602
A/Taipei/0046/2016	6B.1	KY487436
A/Taipei/0050/2016	6B.2	KY487591
A/Taipei/0054/2016	6B.1	KY487403
A/Taipei/0055/2016	6B.2	KY487233
A/Taipei/0056/2016	6B.1	KY615515
A/Taipei/0059/2016	6B.2	KY615586
A/Taipei/0061/2016	6B.1	KY487248
A/Taipei/0063/2016	6B.2	KY487365

A/Taipei/0067/2016 6B.2 KY487709

		Baltimore 6B.1	Taipei 6B.1	Taipei 6B.2	p-value Baltimore 6B.1 v. Taipei 6B.1	p-value Taipei 6B.1 v. Taipei 6B.2
Age						
	18-49	83.3% (20/24)	80.0% (24/30)	65.0% (13/20)	1	0.3266
	50-64	12.5% (3/24)	13.3% (4/30)	35.0% (7/20)	0.1572	0.5062
	65+	4.2% (1/24)	6.7% (2/30)	0% (0/20)	1	0.5102
Race						
	White	4.2% (1/24)	0% (0/30)	0% (0/20)	0.4444	1
	Black or African American	75.0% (18/24)	0% (0/30)	0% (0/20)	<0.0001	1
	Asian	0% (0/24)	100% (30/30)	100% (20/20)	<0.0001	1
	Other	20.8% (5/24)	0% (0/30)	0% (0/20)	0.0134	1
Gend	er					
	Female	54.2% (13/24)	66.7% (20/30)	75.0% (15/20)	0.4075	0.7536
	Male	45.8% (11/24)	33% (10/30)	25.0% (5/20)		
Vacci	nation					
	Vaccinated	26.1% (6/23)	6.7% (2/30)	5.0% (1/20)	0.065	1
Co-m	orbidities					
	None	41.7% (10/24)	66.7% (20/30)	45.0% (9/20)	0.0987	0.1535
	One	25.0% (6/24)	17% (5/30)	40% (8/20)	0.5104	0.1004
	Multiple	33.3% (8/24)	16.7% (5/30)	15.0% (3/20)	0.2056	1
Pregr	nancy	7.7% (1/13)	0% (0/20)	0% (0/15)	<0.0001	1
Disea	se severity					
	Oxygen supplementation	8.3% (2/24)	0% (0/30)	15.0% (3/20)	0.1929	0.05
	Intubation	0% (0/24)	0% (0/30)	0% (0/20)	1	1
	Inpatient	16.7% (4/24)	13% (4/30)	20% (4/20)	1	0.6974
	Length of stay	3 (1-12)	6 (3-9)	7 (4-9)	0.7143	0.8571
	ICU	0% (0/4)	0% (0/4)	0% (0/4)	1	1
	Pneumonia	8% (2/24)	20% (6/30)	35% (7/20)	0.2771	0.3266
	Death	0% (0/24)	0% (0/30)	0% (0/20)	1	1

Supplementary Table 2. Clinical and demographic characteristics of H1N1 IAV-infected patients at Baltimore and Taipei based on HA clade